| News
Lonza set to manufacture coronavirus drug for Humanigen
15.09.2020
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza is also cooperating with the biotech company Moderna on the development of a promising coronavirus vaccine.

Lonza headquarter in Basel (img: Lonza)
Lonza has secured a contract from the US cancer and infection specialists Humanigen, a press release reveals. Together, the two companies are planning to expand production capacities to manufacture the product candidate lenzilumab.
The drug developed by Humanigen is currently being tested in terms of its suitability to treat the coronavirus. According to information in the press release, it could receive an Emergency Use Authorization before the end of this year. Humanigen is keen to start commercial production activities of the drug at Lonza production facilities in 2021.
“We are ramping up our manufacturing efforts for lenzilumab, our lead drug candidate, and this collaboration with Lonza, a global manufacturing leader with expertise in technology transfer and an established track record of working with regulatory bodies for approved and commercialized products, comes at a crucial time to meet production demand for COVID-19 therapeutics this winter.”, comments Cameron Durrant, CEO of Humanigen, in the press release.
Humanigen is not the first company to make use of Lonza’s expertise in the production of a potential coronavirus therapeutic. Moderna is also working together with Lonza on the development of its coronavirus vaccine candidate. The US biotech company recently established a Swiss subsidiary, which is located close to Lonza in Basel.
The vaccine candidate from Moderna is regarded as particularly promising. The Swiss government has already signed a contract with Moderna allowing it to acquire 4.5 million doses, provided of course that the vaccine candidate is awarded authorization for the Swiss market.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More